NURS 6630 Assessing and Treating Patients With Anxiety Disorders Decision #3

NURS 6630 Assessing and Treating Patients With Anxiety Disorders Decision

Selected Decision and Rationale

The ultimate decision was to continue administering the patient’s existing paroxetine dose while closely monitoring them for signs that could suggest the need for supplementary anxiety medication. The patient demonstrated a noteworthy alleviation of anxiety symptoms by 61 percent, which indicates an acceptable degree of adherence and tolerance to the prescribed drug. Empirical data indicates that paroxetine is a very effective intervention for alleviating symptoms of anxiety (Bandelow, 2020). Patients often experience significant relief of symptoms after more than 50% of them have been resolved (Lee & Stein, 2022). To maximize the therapeutic advantages and minimize the likelihood of enduring unpleasant effects, strict adherence to the medication’s recommended dose and treatment regimen is ideal (Szuhany & Simon, 2022).

Since the person had already seen over fifty percent reduction in symptoms, increasing the dose to thirty milligrams was unnecessary. A link has been shown between surpassing the authorized amount of intake and higher levels of toxicity, as well as negative consequences (Creswell et al., 2020). The patient’s absence of any discernible improvement after receiving the whole prescribed amount ruled out any possibility of considering an alternate therapy. Administering Buspirone to this person is contraindicated due to the high likelihood of developing drug resistance (Melaragno, 2021).

Expected Outcome

The patient is expected to have improved control of anxiety symptoms by continuing to take Paxil at the same dosage (Garakani et al., 2020). The individual is expected to have a HAM-A score of around 7, indicating mild or insignificant anxiety.

Ethical Consideration

The patient conveyed contentment with the efficacy of the drug in mitigating her anxiety symptoms (Bandelow, 2020). Carers must prioritize patient autonomy while stressing the need to adhere to the pharmaceutical regimen to enhance care outcomes (McGowan, 2020).